Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

Summary

The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.

Timeline

Start

2025-02-04

Primary completion

2026-01-20

Completion

2026-01-20

Publications

• Chen A, Baccei C, Baccei J, Broadhead A, Lorrain KI, Poon MM, Roppe J, Schrader TO, Stebbins KJ, Valdez L, Xiong Y, Lorrain DS. Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders. J Med Chem. 2026 Jun 29. doi: 10.1021/acs.jmedchem.6c01049. Online ahead of print.

Drugs

Indications